Virtual Library

Start Your Search

Kazuo Nakagawa



Author of

  • +

    P04 - Early Stage/Localized Disease - Perioperative Therapy (Neoadjuvant Therapy, Surgery, Adjuvant Therapy) (ID 113)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Early Stage/Localized Disease
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P04.07 - Long-term Postoperative Prognosis of Adenocarcinoma in Situ and Minimally Invasive Adenocarcinoma of Lung (ID 2527)

      00:00 - 00:00  |  Author(s): Kazuo Nakagawa

      • Abstract
      • Slides

      Introduction

      Five-year postoperative recurrence-free rates for cases of resected lung adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been known to be almost 100%. However, long-term results have not been reported. We analyzed long-term postoperative prognosis of resected cases of AIS and MIA.

      Methods

      We reviewed pathological findings of 4,768 patients who underwent resection for lung cancer between 1998 and 2010. Of these patients, 524 patients with curative resection for AIS (207 cases, 39.5%) and MIA (317 cases, 60.5%) were enrolled in this study. Postoperative recurrence and survival were retrospectively analyzed.

      Results

      For AIS / MIA cases, 142 (68.6%) / 200 (63.1%) were females (p = 0.01), and 112 (54.1%) / 117 (36.9%) underwent sublobar resections (p < 0.01). Average pathological total tumor diameter was 13.8±5.7 / 16.2±5.1 mm (p < 0.01), and median postoperative follow-up periods were 100 (range: 1-237) / 101 (range: 1-210) months for AIS / MIA cases. No recurrence of lung cancer was observed in either AIS or MIA patients. For AIS / MIA cases, estimated 10-year postoperative disease-specific survival rates were 100% / 100% (p = 0.72), overall survival rates were 95.3% / 97.8% (p = 0.94). Estimated incidence rates of metachronous secondary primary lung cancer at 10 years after surgery were 5.6% / 7.7% for AIS / MIA cases (p = 0.44).

      Conclusion

      For cases of AIS and MIA, risk of recurrence is quite low after more than 5 years from curative resection, although development of metachronous secondary primary lung cancer should be noted.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P26 - Mesothelioma, Thymoma and Other Thoracic Malignancies - Thymic Malignancies (ID 218)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P26.09 - Is Thymomectomy alone through Video-Assisted Thoracic Surgery Appropriate for Clinical Stage I (T1N0M0) Thymoma 5cm or Less? (ID 3450)

      00:00 - 00:00  |  Presenting Author(s): Kazuo Nakagawa

      • Abstract
      • Slides

      Introduction

      The optimal mode of resection for thymoma in nonmyasthenic patients remains unclear. Resection of thymoma involves two components: mode of resection and the surgical approach. There are two modes of resection [with total thymectomy (thymothymomectomy) and without total thymectomy (thymomectomy)], and two surgical approaches (median sternotomy and minimally invasive). The aim of this study was to explore whether or not thymomectomy alone through video-assisted thoracic surgery (VATS) is a relevant option for patients with clinical stage I (T1N0M0) thymoma in the TNM classification.

      Methods

      Between 1995 and 2019, 327 patients underwent resection for thymic epithelial tumors at National Cancer Center Hospital, Tokyo, Japan. Among them, 102 patients with clinical stage I (T1N0M0) nonmyasthenic thymoma 5cm or less who underwent thymomectomy through VATS were included in this study. We investigated surgical and oncological outcomes.

      Results

      The patients consisted of 44 men (43.1%) and 58 women (56.9%) with a median age of 62 years (interquartile range [IQR]: 52-69 years). All thymomectomies were performed through either complete VATS with 3 ports or hybrid VATS (incision, 5-8 cm in the fourth intercostal space at the anterior axillary line). The distribution of histologic subtype was type A (n = 17, 16.7%), type AB (n =43, 42.2%), type B1 (n = 18, 17.6%), type B2 (n = 17, 16.7%), and type B3 (n = 6.9%). The median tumor size was 3.1 cm (IQR: 2.4-4.0 cm). In terms of perioperative findings, the median blood loss was 16 ml (range: 5-30 ml) and the median operative time was 85 min (IQR: 71-103 min). Only one patient converted to open thoracotomy due to intra-operative bleeding. There were no operative deaths. The median length of the postoperative hospital stay was 3 days (IQR: 3-4 days). The morbidity rate was 0% and the 30-day mortality rate was 0%. The median follow-up time was 61 months (IQR: 23-98 months). No patients developed postoperative myasthenia gravis. Furthermore, no patients experienced a recurrence of thymoma. Hence, the 5-year freedom from recurrence was 100%.

      Conclusion

      Thymomectomy alone through VATS is acceptable for clinical stage I thymoma 5cm or less with regard to both surgical and oncological outcomes. For nonmyasthenic patients with thymoma, removal of all normal thymus might be unnecessary. Further studies are needed to evaluate long-term outcomes.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.